ArticleBMC infectious diseases2025
Vitamin C is associated with improved outcomes in patients with sepsis-induced myocardial injury: insights from the MIMIC-IV database.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundVitamin C (VC) is a water-soluble, essential micronutrient with multiple important physiological functions. Numerous studies have shown that VC deficiency is closely associated with adverse clinical outcomes in critically ill patients. Due to the extreme oxidative stress and inflammatory response associated with sepsis and its complications, which lead to a rapid depletion of VC. This study aims to explore whether VC supplementation can reduce the mortality of patients with sepsis-induced myocardial injury (SIMI).
methodsThis study used the MIMIC-IV database to extract data of patients with SIMI and conducted a retrospective cohort study. The patients were divided into the VC administration group (VC group) and the non-VC administration group (non-VC group). The study adopted the multiple imputation method to handle the missing data and balanced the baseline characteristics between the two groups using propensity score matching (PSM). The primary outcome was 28-day all-cause mortality, and the secondary outcome included 90-day and 1-year all-cause mortality. Univariate and multivariable Cox proportional hazards regression models were used to evaluate the association between VC administration and mortality in patients with SIMI, and further analyzed the impact of VC dosage on clinical outcomes. The results were visualized using Kaplan-Meier survival curve. Subgroup analysis was conducted to explore the differences in therapeutic efficacy of VC among different populations.
resultsThere were a total of 1488 patients in the final cohort who met the SIMI criteria. After PSM, 129 patients who received VC were matched with 129 non-VC patients. Kaplan-Meier survival curve analysis showed that the VC group had significantly reduced mortality rates at 28 days (27.132% vs. 9.302%, p < 0.001), 90 days (33.333% vs. 16.279%, p < 0.001) and 1 year (44.186% vs. 27.132%, p < 0.001). Multivariable Cox regression analysis further confirmed that VC administration significantly reduced 28-day (HR = 0.20, 95% CI [0.10, 0.41]), 90-day (HR = 0.25, 95% CI [0.14, 0.43]) and 1-year mortality risk (HR = 0.32, 95% CI [0.20, 0.50]). Regarding dosage, the 28-day and 90-day mortality of SIMI patients in the high-dose group were obviously lower than those in the low-dose group, whereas no significant difference was observed in 1-year mortality between the two groups. Subgroup analysis showed a consistent benefit of VC across most populations.
conclusionThe administration of VC was associated with significantly reduced 28-day, 90-day, and 1-year mortality in patients with SIMI, and high-dose group conferred a greater benefit than low-dose group in the short term.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.